Ann: Update on BLA for Graft Versus Host Disease, page-820

Todays market cap is $382.6m, 814m shares on issue, not counting all the options etc.
Debts $90m plus interest. Say $110m
382-110 = $272m. Any commercial approval the company needs to pay $50m to the new owners of Osiris 272-50 = $222m.
Still 10x over valued IMO.

What about income? $8m pa in royalties, overall losses around $65m pa
Obviously creditors are never going to get their money back by keeping it going. Cease operations and sell the inventory to Temcell?
If the creditors take control of the company then the shares are going to be worth very little IMO, unless buyer can be found for the IP.

Investors have a choice. Either quit now or ante up for the next trial.
Will the next trial in adults be successful? If it's randomized and properly controlled, it's a coin toss again. That's the real reason SI has avoided it until he painted himself into a corner with the FDA and creditors. Investors are along for the ride.